Phase 2 N=52 Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Metastatic Breast Cancer · Locally Advanced Breast Cancer
Primary: Progression Free Survival (PFS) Time — 4.80 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=49 Acamprosate to Reduce Symptoms of Alcohol Withdrawal
Alcohol-Related Disorders · Alcohol Dependence · Alcoholism
Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine
Phase 2 N=357 Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
Chronic Hepatitis C
Primary: Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT) — 35.0; 6.3; 16.3; 13.4 Percent of participants
Phase 2 N=21 Beta-Cell Function and Sitagliptin Trial (BEST)
Type 2 Diabetes Mellitus
Primary: Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR — 80.4; 71.2 index of beta-cell function
Phase 2 N=158 Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
Multiple Myeloma
Primary: Number of Patients With Combined Complete Response and Very Good Partial Response — 21; 23; 13; 9 participants
Phase 2 N=12 A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
HIV-1 Infection
Primary: Virological Response[Viral Load <50 Copies/mL, TLOVR] — 11; 1 Participants
Phase 2 N=106 A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression Free Survival During Maintenance Phase — 3.2; 3.2 months — p=0.1815
Phase 2 N=28 Zalutumumab in Head and Neck Cancer
Head and Neck Neoplasms
Primary: Adverse Events — 4; 4; 5; 4 participants
Phase 2 N=132 A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Malignant Melanoma
Primary: Best Overall Response (BOR) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 52.3 Percentage of participants
Phase 2 N=44 Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: 4-month Progression Free Survival (PFS) Rate — 49 percentage of patients
Phase 2 N=137 Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients
Dry Eye Syndromes
Primary: Percentage of Patients With Clinical Success at Month 6 — 64.3; 58.1 Percentage of Patients
Phase 2 N=120 An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation
Functional Gastrointestinal Disorders · Constipation
Primary: Responder of Complete Spontaneous Bowel Movement (CSBM) — 26; 5; 34; 55 participants — p=<0.05
Phase 2 N=97 A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation
Constipation
Primary: Responder for Complete Spontaneous Bowel Movement (CSBM) — 10; 14; 17; 22 participants — p=<0.05
Phase 2 N=208 Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate
Rheumatoid Arthritis
Primary: ACR20 Response at Week 12 — 24; 22; 30; 24 Participants
Phase 2 N=32 Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
Asthma
Primary: Number of Patients Reported to Have Adverse Events — 11; 6; 11 participants